Skip to Content

Invega Sustenna Approval History

FDA Approved: Yes (First approved July 31, 2009)
Brand name: Invega Sustenna
Generic name: paliperidone palmitate
Dosage form: Extended-Release Injectable Suspension
Company: Janssen Pharmaceuticals, Inc.
Treatment for: Schizophrenia, Schizoaffective Disorder

Invega Sustenna (1-month paliperidone palmitate) is a long-acting injectable atypical antipsychotic indicated for the treatment of schizophrenia and schizoaffective disorder.

Development History and FDA Approval Process for Invega Sustenna

DateArticle
Nov 13, 2014Approval FDA Approves sNDA for Invega Sustenna (paliperidone palmitate) for Schizoaffective Disorder
Aug  3, 2009Approval FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide